An across Factor Normalization Based SVD Approach to Analysis of Gene Expression Profiles for Uncovering Biomarkers in Ovarian Carcinoma Chemotherapy Responses

Analyzing microarray data to identify interesting genes is a well-established methodology but often results in inconsistent conclusions and even fails because of the variations of experimental conditions. This study proposes an across factor normalization based singular value decomposition approach to microarray data analysis. The approach has been applied to analyze gene expression profiles to identify differentially expressed genes associated with Ovarian Carcinoma chemotherapy responses. The influences of experimental conditions are identified by correlations analysis and Friedman'M test and illustrated by Scatter Plots. These influences are then removed by across factor normalization. Experimental results showed that after across factor normalization, the samples associated with different chemotherapy responses are significantly clustered together and genes linked to differential chemotherapy responses are identified.

[1]  J. Phan,et al.  Reproducibility of Differential Gene Detection across Multiple Microarray Studies , 2007, 2007 29th Annual International Conference of the IEEE Engineering in Medicine and Biology Society.

[2]  Trevor Hastie,et al.  Gene expression patterns in ovarian carcinomas. , 2003, Molecular biology of the cell.

[3]  Neal S. Holter,et al.  Fundamental patterns underlying gene expression profiles: simplicity from complexity. , 2000, Proceedings of the National Academy of Sciences of the United States of America.

[4]  D. Botstein,et al.  Singular value decomposition for genome-wide expression data processing and modeling. , 2000, Proceedings of the National Academy of Sciences of the United States of America.

[5]  P. Hall,et al.  Risk of leukemia after platinum-based chemotherapy for ovarian cancer. , 1999, The New England journal of medicine.

[6]  M. Gore,et al.  Part II: chemotherapy for epithelial ovarian cancer-treatment of recurrent disease. , 2002, The Lancet. Oncology.

[7]  N. Maggiano,et al.  Increased cyclooxygenase-2 (COX-2) expression is associated with chemotherapy resistance and outcome in ovarian cancer patients. , 2002, Annals of oncology : official journal of the European Society for Medical Oncology.

[8]  Anne-Marie Mes-Masson,et al.  Microarray analysis of gene expression mirrors the biology of an ovarian cancer model , 2001, Oncogene.

[9]  P. Schwartz,et al.  Neoadjuvant chemotherapy for advanced ovarian cancer: long-term survival. , 1999, Gynecologic oncology.

[10]  D. Cruickshank,et al.  Mature results of a randomized trial of two doses of cisplatin for the treatment of ovarian cancer. Scottish Gynecology Cancer Trials Group. , 1996, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[11]  Luis Mateus Rocha,et al.  Singular value decomposition and principal component analysis , 2003 .

[12]  J. Berek,et al.  Assessment of dose-intensive therapy in suboptimally debulked ovarian cancer: a Gynecologic Oncology Group study. , 1995, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[13]  D. Lockhart,et al.  Analysis of gene expression profiles in normal and neoplastic ovarian tissue samples identifies candidate molecular markers of epithelial ovarian cancer. , 2001, Proceedings of the National Academy of Sciences of the United States of America.

[14]  C. Tropé,et al.  Adjuvant chemotherapy for early-stage ovarian cancer: review of the literature. , 2007, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[15]  M. van Glabbeke,et al.  Predictors of response to subsequent chemotherapy in platinum pretreated ovarian cancer: a multivariate analysis of 704 patients [seecomments]. , 1997, Annals of oncology : official journal of the European Society for Medical Oncology.

[16]  David I. Smith.  Transcriptional profiling develops molecular signatures for ovarian tumors. , 2002, Cytometry.

[17]  Kathleen R. Cho,et al.  Gene expression in ovarian cancer reflects both morphology and biological behavior, distinguishing clear cell from other poor-prognosis ovarian carcinomas. , 2002, Cancer research.